ReviewHeart failure reviews2026
Atrial fibrillation in transthyretin amyloid cardiomyopathy: marker of disease severity and implications for multidomain reassessment.
Review in Heart failure reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation or flutter (AF/AFL) affects approximately 56% to 71% of patients with transthyretin amyloid cardiomyopathy (ATTR-CM), with prevalence rising in more advanced disease. AF usually arises on a background of amyloid atrial cardiomyopathy: atrial infiltration, increased stiffness, impaired reservoir and contractile mechanics, and a prothrombotic milieu present even in sinus rhythm. Whether AF contributes independently to mortality remains unsettled. Unadjusted analyses show higher mortality or event rates with AF, inconsistently significant; the association attenuates once amyloid severity is accounted for in single-center and trial datasets. The largest dataset, reported only as a conference abstract, is the exception: an association with a composite including cardiovascular hospitalization persisted after adjustment for stage. Its clinical relevance may lie less in mortality prediction than in symptoms, heart failure events, and thromboembolism. Conventional risk stratification performs poorly: CHA
Indexed as
Identifiers
42734712What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.